Transition from Unfractionated Heparin to Low Molecular Weight Heparins

Thromb Haemost 2002; 88(03): 539-540
DOI: 10.1055/s-0037-1613252

Letters to the Editor

Schattauer GmbH

William A. Ghali

¹Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

,

Andre Pannatier

²The Faculty of Medicine, University of Lausanne, Lausanne, Switzerland

,

Ross T. Tsuyuki

³The Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada

,

Russell D. Hull

¹Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

,

Elizabeth MacKay

¹Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

,

Hude Quan

¹Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

,

Jacques Cornuz

²The Faculty of Medicine, University of Lausanne, Lausanne, Switzerland

References
1 Weitz JI. Drug Therapy: Low-Molecular-Weight Heparins. N Engl J Med 1997; 337: 688-99.
2 Geerts WH, Jay RM, Code KI. et al. A Comparison of Low-Dose Heparin with Low-Molecular-Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N Engl J Med 1996; 335: 701-7.
3 Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis. A meta-analysis of randomized controlled trials. Ann Intern Med 1999; 130: 800-9.
4 Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low molecular weight heparin in acute coronary syndromes without ST elevation: a meta-analysis. Lancet 2000; 355: 1936-42.
5 Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999; 130: 789-99.